Objective: To explore the protective effect of α-obscurine, an active component of Lycopodium on myocardial ischemia-reperfusion (MI/R) injury via anti-inflammatory and anti-oxidant ways. Methods: Wistar rats were intragastrically administered with 1 mL of sterile water or water containing 2.5 mg·kg-1 or 5 mg·kg-1 α-obscurine for 1 week. Ramipril 1 mg·kg-1 was used as a positive control. The left anterior descending branch of the heart was ligated for 30 min and reperfused for 3 h. Echocardiograph was employed to test the the ejection fraction (EF, %), short axis shortening fraction (FS, %), left ventricular systolic pressure (LVSP, mmHg) and left ventricular end diastolic pressure (LVEDP, mmHg). The volume of myocardial infarction was indicated with Evans blue staining. The kits detect total reduced glutathione (GSH), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), superoxide dismutase (SOD) and malondialdehyde (MDA) in serum or myocardial tissue. ELISA was used to test serum creatine kinase-isoenzyme (CK-Mb), troponin T (cTnT), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and prostaglandin E2 (PGE2). Western blotting detects the protein expression of cyclooxygenase 2 (COX-2), metal matrix protease (MMP)-2 and MMP-9. Results: Compared with sham operation control group, EF, FS, and LVSP in MI/R group were significantly decreased, while the LVEDP was significantly increased (P<0.05). α-obscurine could effectively reverse these echocardiographic indexes (P<0.05). α-obscurine also effectively reduced the infarct size of MI/R rats and the serum indicators of myocardial injury such as CK-Mb, cTnT, AST and LDH (P<0.05). α-obscurine reduced the serum MDA with elevated MI/R, increased the reduced serum SOD and myocardial GSH, and alleviated the oxidative stress in MI/R rats (P<0.05). Elevated serum inflammation markers TNF-α, IL-1β, IL-6, PEG2 and myocardial inflammation marker Cox-2 were significantly reduced under 5 mg·kg-1·d-1 α-obscurine treatment (P<0.05). It was further found that metalloproteinase (MMP)-2 and MMP-9 with elevated MI/R were also reduced by α-obscurine (P<0.05). Conclusion: Our results show that α-obscurine could effectively reduce oxidative stress and inflammation, and improve myocardial damage caused by MI/R. The inhibition of MMP-2 and MMP-9 may be its mechanism of action.
[1] VIRANI SS, ALONSO A, BENJAMIN EJ, et al. Heart disease and stroke statistics-2020 update: a report from the american heart association[J].Circulation, 2020, 141(9):e139
[2] GUNATA M, PARLAKPINAR H. A review of myocardial ischaemia/reperfusion injury: pathophysiology, experimental models, biomarkers, genetics and pharmacological treatment[J].Cell Biochem Funct, 2021, 39(2):190
[3] NAITO H, NOJIMA T, FUJISAKI N, et al. Therapeutic strategies for ischemia reperfusion injury in emergency medicine[J].Acute Med Surg, 2020, 7(1):e501
[4] 刘静, 年华, 徐熠, 等. 伸筋草生物碱对佐剂性关节炎大鼠的抗炎作用及机制研究[J].药物评价研究, 2019, 42(5):869
LIU J, NIAN H, XU Y, et al. Anti-inflammatory effect and mechanism of Shenjincao alkaloids on adjuvant arthritis rats [J].Drug Eval Res, 2019, 42(5):869
[5] JO A, EEN KIM C, LEE M. Serratane triterpenoids isolated from Lycopodium clavatum by bioactivity-guided fractionation attenuate the production of inflammatory mediators[J].Bioorg Chem, 2020, 96(96):103632
[6] 王毅红, 张春生, 谭萍, 等. 石松黄酮类化合物的抗氧化作用研究[J].湖南文理学院学报(自然科学版), 2013, 25(2):30
WANG YH, ZHANG CS, TAN P, et al.On anti-oxidation of the Lycopodium japonicum thunb flavonoids [J].J Hunan Univ Arts(Nat Sci Ed), 2013, 25(2):30
[7] 邹桂欣, 尤献民, 吴怡. DPPH·法评价伸筋草不同提取物清除自由基的能力[J].药物评价研究, 2012, 35(5):359
ZOU GX, YOU XM, WU Y. Evaluation of free radical scavenging ability of different extracts from Lycopodii Herba by DPPH·assay [J].Drug Eval Res, 2012, 35(5):359
[8] 邹桂欣, 尤献民, 邸子真. 伸筋草提取物中玉柏碱在大鼠体内的药动学研究[J].药物评价研究, 2013, 36(6):410
ZOU GX, YOU XM, DI ZZ. In vivo pharmacokinetic study on α-obscurine in rats after ig administration of Lycopodium japonicum extract [J].Drug Eval Res, 2013, 36(6):410
[9] 张妍妍, 毕悦, 尹丽颖, 等. 伸筋草总生物碱的提取纯化与急性毒性及抗炎活性研究[J].中医药学报, 2020, 48(6):14
ZHANG YY, BI Y, YIN LY, et al. Extraction and purification of total alkaloids from Lycopodii Herba and the study on its acute toxicity and anti-inflammatory activity [J].J Chin Med Pharmacol, 2020, 48(6):14
[10] BANERJEE A, PATHAK S, JOTHIMANI G, et al. Antiproliferative effects of combinational therapy of Lycopodium clavatum and quercetin in colon cancer cells[J].J Basic Clin Physiol Pharmacol, 2020, 31(4):20190193
[11] DELEON-PENNELL KY, ALTARA R, YABLUCHANSKIY A, et al. The circular relationship between matrix metalloproteinase-9 and inflammation following myocardial infarction[J].IUBMB Life, 2015, 67(8):611
[12] LI X, KANG M, MA N, et al. Identification and analysis of chemical constituents and rat serum metabolites in Lycopodium clavatum using UPLC-Q-TOF/MS combined with multiple data-processing approaches[J].Evid Based Comp Alternat Med, 2019, 2019:5165029
[13] JIANG F, QI B, DING N, et al. Lycopodium alkaloids from Huperzia Serrata[J].Fitoterapia, 2019, 137(137):104277
[14] KIM THU D, VUI DT, NGOC HN, et al. The use of Huperzia species for the treatment of Alzheimer's disease[J].J Basic Clin Physiol Pharmacol, 2019, 31(3):20190159
[15] JAYARAJ RL, BEIRAM R, AZIMULLAH S, et al. Lycopodium attenuates loss of dopaminergic neurons by suppressing oxidative stress and neuroinflammation in a rat model of parkinson's disease[J].Molecules, 2019, 24(11):2182
[16] 邹桂欣, 尤献民, 刘晶, 等. 伸筋草提取物及主要药效成分对家兔血小板聚集影响[J].亚太传统医药, 2012, 8(11):10
ZOU GX, YOU XM, LIU J, et al. Effects of extracts and active constituent from Lycopodium on platelet aggregation in rabbit [J].Asia-Pacific Tradit Med, 2012, 8(11):10
[17] FLUCK F, AUGUSTIN AM, BLEY T, et al. Current treatment options in acute limb ischemia[J].Rofo, 2020, 192(4):319
[18] POWERS WJ. Acute ischemic stroke[J].N Engl J Med, 2020, 383(3):252
[19] WU Y, LIU H, WANG X. Cardioprotection of pharmacological postconditioning on myocardial ischemia/reperfusion injury[J].Life Sci, 2021, 264(264):118628
[20] SCOFIELD SLC, DALAL S, LIM KA, et al. Exogenous ubiquitin reduces inflammatory response and preserves myocardial function 3 days post-ischemia-reperfusion injury[J].Am J Physiol Heart Circ Physiol, 2019, 316(3):H617
[21] CHAN BYH, ROCZKOWSKY A, CHO WJ, et al. Junctophilin-2 is a target of matrix metalloproteinase-2 in myocardial ischemia-reperfusion injury[J].Basic Res Cardiol, 2019, 114(6):42
[22] GÖMÖRI K, SZABADOS T, KENYERES É, et al. Cardioprotective effect of novel matrix metalloproteinase inhibitors[J].Int J Mol Sci, 2020, 21(19): 6990
